269 related articles for article (PubMed ID: 12418935)
1. An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients.
Koro CE; Fedder DO; L'Italien GJ; Weiss S; Magder LS; Kreyenbuhl J; Revicki D; Buchanan RW
Arch Gen Psychiatry; 2002 Nov; 59(11):1021-6. PubMed ID: 12418935
[TBL] [Abstract][Full Text] [Related]
2. Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database.
Gianfrancesco FD; Grogg AL; Mahmoud RA; Wang RH; Nasrallah HA
J Clin Psychiatry; 2002 Oct; 63(10):920-30. PubMed ID: 12416602
[TBL] [Abstract][Full Text] [Related]
3. A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year.
Meyer JM
J Clin Psychiatry; 2002 May; 63(5):425-33. PubMed ID: 12019668
[TBL] [Abstract][Full Text] [Related]
4. Association between antipsychotic treatment and hyperlipidemia among California Medicaid patients with schizophrenia.
Lambert BL; Chang KY; Tafesse E; Carson W
J Clin Psychopharmacol; 2005 Feb; 25(1):12-8. PubMed ID: 15643095
[TBL] [Abstract][Full Text] [Related]
5. Weight gain in patients with schizophrenia treated with risperidone, olanzapine, quetiapine or haloperidol: results of the EIRE study.
Bobes J; Rejas J; Garcia-Garcia M; Rico-Villademoros F; García-Portilla MP; Fernández I; Hernández G;
Schizophr Res; 2003 Jul; 62(1-2):77-88. PubMed ID: 12765747
[TBL] [Abstract][Full Text] [Related]
6. Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study.
Koro CE; Fedder DO; L'Italien GJ; Weiss SS; Magder LS; Kreyenbuhl J; Revicki DA; Buchanan RW
BMJ; 2002 Aug; 325(7358):243. PubMed ID: 12153919
[TBL] [Abstract][Full Text] [Related]
7. Hyperlipidemia following treatment with antipsychotic medications.
Olfson M; Marcus SC; Corey-Lisle P; Tuomari AV; Hines P; L'Italien GJ
Am J Psychiatry; 2006 Oct; 163(10):1821-5. PubMed ID: 17012695
[TBL] [Abstract][Full Text] [Related]
8. Strategies for switching from conventional antipsychotic drugs or risperidone to olanzapine.
Kinon BJ; Basson BR; Gilmore JA; Malcolm S; Stauffer VL
J Clin Psychiatry; 2000 Nov; 61(11):833-40. PubMed ID: 11105736
[TBL] [Abstract][Full Text] [Related]
9. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder.
Conley RR; Mahmoud R
Am J Psychiatry; 2001 May; 158(5):765-74. PubMed ID: 11329400
[TBL] [Abstract][Full Text] [Related]
10. Antipsychotic exposure and type 2 diabetes among patients with schizophrenia: a matched case-control study of California Medicaid claims.
Lambert BL; Chou CH; Chang KY; Tafesse E; Carson W
Pharmacoepidemiol Drug Saf; 2005 Jun; 14(6):417-25. PubMed ID: 15786516
[TBL] [Abstract][Full Text] [Related]
11. Measurement of simple reaction time in antipsychotic treatment of patients with schizophrenia.
Kores Plesnicar B; Zalar B; Tomori M; Krajnc I
Wien Klin Wochenschr; 2003 Jan; 115(1-2):58-62. PubMed ID: 12658913
[TBL] [Abstract][Full Text] [Related]
12. Effects of olanzapine on prolactin levels of female patients with schizophrenia treated with risperidone.
Kim KS; Pae CU; Chae JH; Bahk WM; Jun TY; Kim DJ; Dickson RA
J Clin Psychiatry; 2002 May; 63(5):408-13. PubMed ID: 12019665
[TBL] [Abstract][Full Text] [Related]
13. [Therapy with antipsychotic drugs as a risk factor for diabetes in schizophrenia: a case-control study].
Rubio G; Gómez-de-la-Cámara A; Ledesma F; Burón JA; Rodríguez-Morales A; Martínez-Junquera G;
Med Clin (Barc); 2006 Apr; 126(12):441-4. PubMed ID: 16620729
[TBL] [Abstract][Full Text] [Related]
14. Differential effects of antipsychotic agents on the risk of development of type 2 diabetes mellitus in patients with mood disorders.
Gianfrancesco F; Grogg A; Mahmoud R; Wang RH; Meletiche D
Clin Ther; 2003 Apr; 25(4):1150-71. PubMed ID: 12809963
[TBL] [Abstract][Full Text] [Related]
15. Atypical antipsychotics and cardiovascular risk in schizophrenic patients.
Bouchard RH; Demers MF; Simoneau I; Alméras N; Villeneuve J; Mottard JP; Cadrin C; Lemieux I; Després JP
J Clin Psychopharmacol; 2001 Feb; 21(1):110-1. PubMed ID: 11199934
[No Abstract] [Full Text] [Related]
16. Risperidone versus other atypical antipsychotic medication for schizophrenia.
Gilbody SM; Bagnall AM; Duggan L; Tuunainen A
Cochrane Database Syst Rev; 2000; (3):CD002306. PubMed ID: 10908551
[TBL] [Abstract][Full Text] [Related]
17. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder.
Volavka J; Czobor P; Sheitman B; Lindenmayer JP; Citrome L; McEvoy JP; Cooper TB; Chakos M; Lieberman JA
Am J Psychiatry; 2002 Feb; 159(2):255-62. PubMed ID: 11823268
[TBL] [Abstract][Full Text] [Related]
18. Comparative study of the development of diabetes mellitus in patients taking risperidone and olanzapine.
Fuller MA; Shermock KM; Secic M; Grogg AL
Pharmacotherapy; 2003 Aug; 23(8):1037-43. PubMed ID: 12921249
[TBL] [Abstract][Full Text] [Related]
19. Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia.
Casey DE; Daniel DG; Wassef AA; Tracy KA; Wozniak P; Sommerville KW
Neuropsychopharmacology; 2003 Jan; 28(1):182-92. PubMed ID: 12496955
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of olanzapine and risperidone for treatment-refractory schizophrenia among long-stay state hospital patients.
Dinakar HS; Sobel RN; Bopp JH; Daniels A; Mauro S
Psychiatr Serv; 2002 Jun; 53(6):755-7. PubMed ID: 12045315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
